Oncology

Ribociclib plus letrozole improved progression free survival in patients with HR+/HER2 advanced or metastatic breast cancer.

The FDA has approved Novartis’ Kisqali (ribociclib), in combination with an aromatase inhibitor as initial endocrine-based therapy treatment, for the treatment of breast cancer.

BET-inhibitors and immune-based treatments may improve outcomes in patients with blood cancer.

Neoadjuvant chemotherapy decreased recurrence and increased survival in African American patients.

Melanoma survivors more likely to limit sun exposure than individuals without a history of skin cancer.

Target may lead to the development of new drugs that inhibit cancer.

A regulatory protein that weakens the immune response to viral RNA presents a new treatment target for cancer.

Extracellular matrix receptors shield cancer cells from harsh environments.

Targeting the immune response to cancer may lead to new immunotherapies.

Targeted and individualized breast cancer treatment is viable.

Many patients with stage 1 and 2 breast cancer are administered aggressive chemotherapy.

Patients with early-stage breast cancer may not need aggressive treatment.

Combination therapy may improve treatment strategies for hepatocellular carcinoma.

Promise seen in targeting protein in PTEN-deficient cancer cells.

Updates on the national performance benchmarks for digital mammography.

Prostate cancer can be subtyped based on cell of origin as luminal A, luminal B, and basal cell subtypes.

Patients with luminal B prostate cancer benefited the most from androgen deprivation therapy.

Treatment shows benefit in patients with low-grade serous cancer.

Early-stage breast cancer patients with low muscle quality and quantity have twice the risk of hospitalization.

Treatment with the myxoma virus reduced tumor burden and led to a modest decrease in disease progression in mice.

Patients who received phone counseling were more likely to quit smoking than patients who received a list of low cost services.

Top news of the week in oncology and cancer drug development.

PI3K inhibitors loaded into nanoparticles provided targeted treatment for head and neck cancers.

Recombinant shell nanoparticles could deliver drugs straight to cancer cells.

Sarcopenia identified as an independent risk factor.

African American patients are more likely to be diagnosed with advanced cancer and have higher mortality.

Premenopausal African American women with a p35 mutation may be at a higher risk of developing breast cancer.

Top news of the day from across the health care landscape.